Cesca Therapeutics (NASDAQ: KOOL) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cesca Therapeutics and Onconova Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cesca Therapeutics 0 1 0 0 2.00
Onconova Therapeutics 0 0 3 0 3.00

Onconova Therapeutics has a consensus price target of $8.00, indicating a potential upside of 412.82%. Given Onconova Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Onconova Therapeutics is more favorable than Cesca Therapeutics.

Earnings & Valuation

This table compares Cesca Therapeutics and Onconova Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cesca Therapeutics $14.00 million 2.40 -$6.73 million ($5.28) -0.64
Onconova Therapeutics $2.36 million 6.27 -$20.55 million ($2.35) -0.66

Cesca Therapeutics has higher revenue and earnings than Onconova Therapeutics. Onconova Therapeutics is trading at a lower price-to-earnings ratio than Cesca Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cesca Therapeutics and Onconova Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cesca Therapeutics -225.90% -33.56% -23.23%
Onconova Therapeutics -762.13% -558.97% -85.62%

Insider & Institutional Ownership

2.4% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Onconova Therapeutics shares are held by institutional investors. 3.9% of Cesca Therapeutics shares are held by insiders. Comparatively, 27.3% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Cesca Therapeutics has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.

Summary

Onconova Therapeutics beats Cesca Therapeutics on 8 of the 13 factors compared between the two stocks.

About Cesca Therapeutics

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive News & Ratings for Cesca Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.